Bioserv Announces Award and Completion of First U.S. Prime Contract

San Diego, CA, 11 February 2016 — Bioserv Corporation, a leading regional provider of pharmaceutical cGMP fill/finish contract manufacturing and related services, is pleased to announce the successful completion of a prime contract with the National Institute of Standards and Technology (NIST)/Biomanufacturing Initiative, an agency of the U.S. Department of Commerce.

The material vialed by Bioserv provides NIST with vials of protein reagents to support research into protein stability and protein structure. To meet the requirements of this award, Bioserv utilized its fill/finish capabilities to handle high-throughput, low-volume filling and automated capping for nested tubes.

Al Hansen, Chairman and CEO of Bioserv Corporation, commented, *"Although we are a small company, we are proud to showcase our skill set and are pleased to have been awarded the contract to perform this important work. Bioserv's capabilities and expertise were a critical piece of both the contract selection process and the successful execution of this contract."*

About NIST

As a non-regulatory agency of the United States Department of Commerce, NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit www.nist.gov.

About the NIST Biomanufacturing Initiative

The objective of the NIST biomanufacturing program is to support the development, manufacturing and regulatory approval of protein therapeutics. The mission is fulfilled through the development of standards, measurement science, and state-of-the-art tools that support advances in development, characterization and manufacturing of protein drugs. The program was developed through close working relationships with members of the U.S. biopharmaceutical industry, the FDA and international standards organizations to assess and authenticate current unmet and future measurement needs related to the manufacturing of protein drugs. NIST has sponsored numerous workshops and conferences involving these industrial and government stakeholders to provide input and feedback on NIST programs. Three major areas of study (Protein Stability, Protein Structure, and Production Cell Variability) for metrology and standards development were identified and are the focus of the program.

About Bioserv Corporation

Founded in 1988 in San Diego, Bioserv Corporation is a leading regional provider of pharmaceutical cGMP contract manufacturing, clinical packaging and cold chain and distribution services. Bioserv has been inspected by FDA, is cGMP FDA—compliant and ISO13485:2003–certified with over 35,000 square feet of facilities. Bioserv's core competencies include aseptic and non-aseptic bulk formulation, filtration, filling, lyophilization, microfluidization, nano-emulsion, and high-shear mixing services to support Pre-Clinical, Phase I and II Clinical Trial drug products, medical device and medical diagnostic reagents and kits, life science "research use only" reagents, as well as labeling, finished goods assembly, kitting and packaging. In addition, Bioserv provides controlled temperature storage and distribution services. Bioserv's expertise in project management and technology transfer services helps clients optimize their manufacturing timelines and schedules to assure that operations perform seamlessly and that product is delivered on time.

www.bioserv.us

Contact: Al Hansen
Bioserv Corporation
Chairman and CEO
1-858-450-3123